Clinical-stage RNAi therapeutics company Silence Therapeutics has announced that its management will attend the Jefferies Global Healthcare Conference, scheduled for 4:55 PM Eastern Time on June 3, 2026. The session will feature an analyst-led fireside chat. Investors can access a live webcast via the company's investor relations webpage, with a replay made available following the event.
Key Pipeline: Divesiran Phase III Data Readout Expected in August The most closely watched asset for Silence Therapeutics is divesiran (SLN124), a siRNA therapy targeting TMPRSS6 for the treatment of polycythemia vera (PV). The company has completed patient enrollment for the Phase II SANRECO trial, with topline results anticipated in August 2026.
PV is a rare myeloproliferative neoplasm with limited treatment options. Divesiran works by inhibiting TMPRSS6 expression to modulate iron metabolism, showing potential to improve erythropoiesis and reduce hematocrit levels. Positive Phase II data would mark the drug's advancement into later-stage clinical development. According to the milestone plan disclosed in the company's 2025 annual report, divesiran is the "highest priority" project.
Early Pipeline: Zerlasiran in Phase III Preparation Another core candidate, zerlasiran (SLN360), aims to lower lipoprotein(a) levels for cardiovascular disease treatment. Phase III preparatory activities were largely completed in 2025, and the company is actively seeking third-party partners to co-advance Phase III development.
Beyond hematologic disorders, the company is progressing several early-stage programs: SLN365 (targeting GPR146) and SLN098 (targeting INHBE) are both expected to report preclinical data in the second quarter of 2026. Additionally, the collaboration with AstraZeneca continues, although AstraZeneca has decided not to pursue further development of SLN312 beyond Phase I, leading Silence to regain global rights to that asset.
Financial Status: Losses Narrowed Significantly, Ample Cash Runway For the first quarter of 2026, the company reported revenue of $0.4 million, primarily from collaboration activities with AstraZeneca. The net loss was $15.0 million ($0.11 per share), a significant improvement from $28.5 million ($0.20 per share) in the same period last year, largely due to substantial reductions in research and development (R&D) and administrative expenses. R&D expenses decreased from $20.8 million to $9.1 million year-over-year, reflecting the completion of zerlasiran's Phase III preparations and a reduction in workforce size.
As of March 31, 2026, the company held approximately $70.1 million in cash, cash equivalents, and short-term investments. Based on the current burn rate, this capital is sufficient to fund operations into 2027.
Analyst Expectation Variance Warrants Attention Notably, there is a discrepancy in market data regarding Silence's first-quarter financial performance. The actual GAAP loss per share reported on May 8 was $0.11, which was significantly better than the $0.32 loss expected by some data platforms and also better than the low-end expectation of $0.54. This indicates that, under GAAP accounting, the company's cost control measures have exceeded market expectations.
Silence Therapeutics is headquartered in London and trades on the Nasdaq under the ticker "SLN," with approximately 88 employees. As of May 26, the company's stock price was $6.72, with a market capitalization of around $317 million. The market will closely watch for additional details provided at the Jefferies conference regarding the divesiran data readout timeline and the progress of the zerlasiran partnership.
Comments